A study in PLOS ONE evaluates the feasibility and impact of a single-dose 9-valent HPV vaccination program in Indonesia, focusing on its potential to reduce cervical cancer rates. The research highlights that a single-dose regimen is cost-effective, logistically simpler, and more accessible, particularly in low-resource settings. It also emphasizes the importance of community engagement and education to address vaccine hesitancy and ensure high coverage. The findings suggest that adopting a single-dose strategy could accelerate HPV vaccine rollout and improve equity in immunization programs. Policymakers and practitioners are encouraged to consider this approach as a viable option for scaling up HPV vaccination efforts globally.